News

In the study, participants taking AMX0035 had a statistically significant slowing of ALS disease progression as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R) compared to placebo (p<0.05),

The status has been provided to DCR-A1AT based on a positive opinion from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA). A1AT deficiency

The latest approval means that XTANDI is indicated for the treatment of three distinct forms of advanced prostate cancer that include non-metastatic and metastatic castration-resistant prostate cancer (CRPC),

Under the terms of the agreement, AstraZeneca has received a payment of $178m from Cheplapharm. The Company may also receive future sales-contingent payments of up to $61m. The

Upon completion of the merger, the merged company would operate under the name Tarveda Therapeutics, Inc. and trade on the Nasdaq Stock Market LLC under the ticker symbol

HemaCare has expertise in the customisation of human-derived biological products and services for biomedical research, drug discovery, and cellular therapy process development. HemaCare provides a range of human

The two phase 3 trials for Jardiance called EMPERIAL-Reduced and EMPERIAL-Preserved were carried out in adults with chronic heart failure with reduced and preserved ejection fraction, respectively. In

The study showed adding Tecentriq (atezolizumab) to Cotellic (cobimetinib) and Zelboraf (vemurafenib) helped to reduce the risk of disease worsening or death, compared to placebo plus Cotellic and

TED is a rare, serious, progressive and vision-threatening autoimmune disease, and is associated with proptosis (eye bulging), diplopia (double vision), blurred vision, pain and facial disfigurement that can